Piramal Pharma Solutions Enhances Manufacturing with Korsch XM-12 Bilayer Tablet Press Acquisition

Piramal Pharma Solutions, a prominent global Contract Development and Manufacturing Organization (CDMO), has announced a significant upgrade to its Morpeth facility located in the UK. The company has recently integrated a state-of-the-art Korsch XM-12 bilayer tablet press, which is set to enhance its formulation capabilities for drug development and manufacturing.

The introduction of the Korsch XM-12 is a strategic move aimed at boosting the facility’s production capacity, particularly in creating fixed-dose combinations and modified-release drug delivery systems. The Morpeth site plays a crucial role in Piramal's operations, providing specialized services for oral solids and hormonal product manufacturing.

The advanced features of the Korsch XM-12 tablet press allow for high-output production of both single-layer and bilayer tablets, with precision and efficiency. One of the innovative elements of this equipment is its advanced sanitary fittings, which are designed specifically for the containment of high-potency Active Pharmaceutical Ingredients (APIs). The XM-12 also includes two different changeover turrets, facilitating quick transitions between product batches, thus improving productivity.

In terms of operational safety and product quality, Piramal has implemented rigorous training protocols for their staff to ensure the effective and safe use of the new tablet press. All personnel, including scientists, operators, and maintenance teams, will participate in detailed training sessions alongside Korsch factory technicians. This training encompasses all aspects of the tablet press operation, including its bilayer and single-layer modes, changeovers, cleaning processes, and future containment testing strategies.

Frank Bugg, Managing Director and Site Head at Piramal Pharma Solutions’ Morpeth facility, emphasized the importance of this upgrade. "In preparation for using the Korsch XM-12, we are ensuring that our teams are well-equipped to handle the press effectively. This will ensure our output meets both industry standards and Piramal's stringent quality requirements."

The XM-12's built-in technology is specifically designed to maintain consistent product quality with minimal operator intervention once essential settings have been established. This contributes to the overall goal of delivering high-quality tablets efficiently and effectively.

Through this significant investment in the Korsch XM-12 bilayer tablet press, Piramal Pharma Solutions reaffirms its commitment to innovation in drug delivery systems and overall operational excellence. The high-precision capabilities of the XM-12 will enable the facility to produce superior-quality tablets at scale, ensuring that the company can meet the growing demand for innovative therapies.

In the broader context, the acquisition of this advanced technology not only aids in the production process but also aligns with Piramal's mission to provide high-quality health solutions while significantly reducing the burden of diseases worldwide.

Conclusion

Piramal Pharma Solutions continues to assert its leadership in the pharmaceutical manufacturing space by investing in cutting-edge technology. The Korsch XM-12 bilayer tablet press is set to play a pivotal role in enhancing the capabilities of the Morpeth facility, allowing Piramal to maintain its standards of excellence in providing safe and effective medications to patients globally.

For more information on Piramal Pharma Solutions and its services, visit their website or follow them on social media platforms like LinkedIn and Facebook.